| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 30,010 | 30,100 | 10:21 | |
| 30,010 | 30,090 | 10:19 |
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Di | Eisai Alzheimer's drug Leqembi shows early signs of momentum shift - Bernstein | ||
| 17.09. | Eisai: Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation | TOKYO, Sept 17, 2025 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that etalanetug (development code: E2814), an investigational anti-MTBR (microtubule... ► Artikel lesen | |
| 17.09. | FDA grants fast track designation to Eisai's Alzheimer's drug | ||
| 12.09. | "New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month | TOKYO, Sept 12, 2025 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the release of a concept movie and new content on the dedicated website for its... ► Artikel lesen | |
| 08.09. | Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025 | E2086 Showed Potential to Improve Wakefulness in People Living with Narcolepsy Type 1TOKYO, Sept 8, 2025 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced... ► Artikel lesen |
